Seren Necla Sevim Wunderlich

Seren Necla Sevim-Wunderlich is a Project Scientist Trainee at Myelo Therapeutics GmbH since September 2023, following a role as Regional Director of Programmes at Nucleate Germany that started in March 2023. Prior experience includes serving as a Marie Sklodowska-Curie PhD Researcher at the Max Delbrück Center from March 2018 to March 2023, where research focused on AAV-mediated gene therapy and CRISPR gene editing to address X-linked chronic granulomatous disease. Academic qualifications include a Doctor of Philosophy in Molecular Medicine from Freie Universität Berlin, a Master of Science in Biotechnology from Chalmers University of Technology, and a Bachelor's degree in Bioengineering from Ege University. Prior roles also encompass positions at AstraZeneca, Ege University, the University of Gothenburg, and Chalmers University as a Student Ambassador.